Royal Bank of Canada reissued their outperform rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a research note published on Tuesday, Benzinga reports. The brokerage currently has a $148.00 price target on the biotechnology company’s stock. Other equities research analysts have also recently issued research reports about the stock. Needham & Company […]
Wedbush began coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a research report report published on Tuesday morning, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $224.00 target price on the biotechnology company’s stock. Wedbush also issued estimates for Sarepta Therapeutics’ Q4 2023 earnings at $0.04 EPS, FY2023 earnings […]
Sarepta Therapeutics (NASDAQ:SRPT) Now Covered by Wedbush theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Acadian Asset Management LLC reduced its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 49.8% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 498 shares of the biotechnology company’s stock after selling 494 shares during the period. Acadian Asset Management LLC’s holdings in Sarepta Therapeutics were worth $57,000 […]
Over a 52-week treatment period, the gene therapy demonstrated robust evidence for a clinically meaningful benefit, including across several prespecified functional secondary end points vs placebo.